KYNB Stock Forecast & Price Target

Kyntra Bio is attractive because its balance sheet has improved materially through the amended NovaQuest royalty deal, leaving pro forma cash of about $53 million and runway into 4Q27, with roughly $100.3 million cash at 1Q26-end and runway into 2H28 cited in the thesis. Its lead CD46 franchise is de-risked by encouraging FG-3246 monotherapy and combination data, plus FG-3180 companion-diagnostic logic, with the key Phase 2 interim readout expected in 4Q26 and designed around a futility analysis in a biomarker-enriched, earlier-line mCRPC population. The second engine, roxadustat for LR-MDS, adds optionality as the only oral option in the indication, while post hoc MATTERHORN data support a sizable market opportunity and diversify the company’s value drivers.

Kyntra Bio is viewed negatively because its value is concentrated in two high-risk assets, with FG-3246 in mCRPC contributing 57% and only a 15% probability of success, while roxadustat in MDS-anemia contributes 43% with a 25% probability of success. The company’s pipeline has already failed to meet clinical efficacy endpoints for FG-3246 and FG-3180, and a safety signal, manufacturing issues, or regulatory pushback could further delay or prevent approval. In addition, it may require additional funding for development and commercialization, face dilutive capital raises, and struggle with IP, competitive, reimbursement, and delisting risks that could limit long-term shareholder value.